Effects of Eprosartan Versus Enalapril in Hypertensive Patients on the Renin-Angiotensin-Aldosterone System and Safety Parameters: Results from a 26-Week, Double-blind, Multicentre Study
- 1 January 1999
- journal article
- clinical trial
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 15 (1), 15-24
- https://doi.org/10.1185/03007999909115169
Abstract
A double-blind comparator study was performed in 528 hypertensive patients [baseline sitting diastolic blood pressure (SitDBP) 95–114 mmHg]. The primary objective was to compare the incidence of drug-related cough in patients treated with enalapril and eprosartan. The secondary objective was to compare antihypertensive efficacy between treatments. This paper reports the effects seen on the safety profile, plasma renin activity, aldosterone and angiotensin II (A-II) in each treatment group. Eprosartan was titrated from 200 mg b.i.d. to 300mg b.i.d. and enalapril from 5mg o.d. to 20 mg o.d. over 12 weeks. Hydrochlorothiazide (HCTZ) 12.5–25 mg o.d. could be added where required to the treatment for the final six weeks of the titration phase if SitDBP ≥ 90 mmHg. Patients received the maximum titrated dosage during the maintenance phase. In the study overall, similar mean changes in blood pressure from baseline were evident with each treatment. Measurement of mean plasma neurohormone levels showed significant increases in renin activity in both groups and statistically significant A-II elevations in the eprosartan group (p < 0.05). Neither eprosartan nor enalapril significantly altered serum lipid profiles or electrolyte levels. Most adverse experiences reported throughout the study were mild or moderate in both treatment groups. Fewer patients receiving eprosartan (4.9%) than enalapril (9.1 %) discontinued treatment because of adverse experiences. In conclusion, the results of this study show that eprosartan is well tolerated. Both eprosartan and enalapril significantly increased plasma renin activity while plasma A-II was elevated in the eprosartan group.Keywords
This publication has 13 references indexed in Scilit:
- Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)The Lancet, 1997
- Inhibition of Sympathetic Outflow by the Angiotensin II Receptor Antagonist, Eprosartan, but Not by Losartan, Valsartan or Irbesartan: Relationship to Differences in Prejunctional Angiotensin II Receptor BlockadePharmacology, 1997
- Controlled Trial of Losartan Given Concomitantly with Different Doses of Hydrochlorothiazide in Hypertensive PatientsBlood Pressure, 1996
- Putative mechanisms of cough after treatment with angiotensin converting enzyme inhibitorsJournal Of Hypertension, 1995
- Angiotensin II receptor antagonists: A new approach to blockade of the renin-angiotensin systemAmerican Heart Journal, 1994
- Bradykinin-mediated effects of ACE inhibitionKidney International, 1992
- Change in cough reflex after treatment with enalapril and ramipril.BMJ, 1989
- Increased cough reflex associated with angiotensin converting enzyme inhibitor cough.BMJ, 1987
- Discrepancy between antihypertensive effect and angiotensin converting enzyme inhibition by captopril.Hypertension, 1980
- Stimulation of ‘irritant’ receptors and afferent C-fibres in the lungs by prostaglandinsNature, 1976